THE LANCET, Vol 355, February 26, 2000 George Perry, Akihiko Nunomura, Arun K Raina, Mark A Smith View Poster Post navigationPreviousPrevious post:Neuroactive neurosteroids as endogenous effectors for the sigma1 (σ1) receptor: Pharmacological evidence and therapeutic opportunities.NextNext post:Sigma-1 receptor ligand 4-phenyl-1-(4-phenylbutyl)-piperidine affords neuroprotection from focal ischemia with prolonged reperfusion.Related PostsAnavex Life Sciences Reports Fiscal 2020 First Quarter Financial Results And Provides Clinical Study UpdatesFebruary 6, 2020Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett SyndromeNovember 6, 2019Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease October 9, 2019Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from the U.S. Rett Syndrome Phase 2 ANAVEX®2-73 StudySeptember 27, 2019
Anavex Life Sciences Reports Fiscal 2020 First Quarter Financial Results And Provides Clinical Study UpdatesFebruary 6, 2020
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett SyndromeNovember 6, 2019
Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease October 9, 2019
Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from the U.S. Rett Syndrome Phase 2 ANAVEX®2-73 StudySeptember 27, 2019
